StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

ARA-290 (Cibinetide)

ARA-290 is a peptide analogue of erythropoietin designed to activate the innate repair receptor, showing potential in reducing neuropathic pain and improving nerve fiber density, particularly in sarcoidosis patients.

neuroprotectionpainanti-inflammatorynerve-repair
Evidence last reviewed: 19 Apr 2026
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on ARA-290 (Cibinetide).
Biomarkers studied
Outcomes directly measured across the evidence records below
Cognitive
Neuroprotection / NGF
Evidence
3 records
Corneal nerve fiber abundance
Patients with sarcoidosis-associated small nerve fiber loss and neuropathic painRCT
PUBMEDModerate

Cibinetide improved corneal nerve fiber area and increased regenerating intraepidermal fibers, indicating potential for disease modification.

Dose: 4 mgDuration: 28 daysForm: Injection
Pain intensity
Patients with moderate-severe neuropathic painRCT
PUBMEDModerate

Subjects reported a clinically meaningful decrease in pain intensity, particularly in the 4 mg group.

Dose: 4 mgDuration: 28 daysForm: Injection
Functional capacity (6-minute walk test)
Patients with sarcoidosis-associated small nerve fiber lossRCT
PUBMEDModerate

Improvement in functional capacity as measured by the 6-minute walk test was observed.

Dose: 4 mgDuration: 28 daysForm: Injection
Forms
Injection
Administered subcutaneously for systemic effects.

Stacks containing ARA-290 (Cibinetide)

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.